Literature DB >> 10177460

Anorganic bovine bone and analogs of bone mineral as implants for craniofacial surgery: a literature review.

N L Fulmer1, G M Bussard, T J Gampper, R F Edlich.   

Abstract

Hydroxyapatite compounds and a new anorganic bovine bone mineral are materials that offer an alternative to autologous bone grafting. Ceramic hydroxyapatite implants are limited in their usefulness due to difficulty in contouring the cortical form and the tendency for the granular form to exist outside the reconstruction site. These limitations have been overcome by the advent of a hydroxyapatite cement paste exhibiting good biocompatibility, contour manipulation, implant stability and osseoinduction. Preliminary studies indicate that a new resorbable anorganic bovine bone mineral with a chemical composition and structure similar to human bone promotes initial bony healing more readily than its synthetic hydroxyapatite counterpart, and therefore may serve as an excellent alternative for craniofacial reconstruction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10177460

Source DB:  PubMed          Journal:  J Long Term Eff Med Implants        ISSN: 1050-6934


  3 in total

1.  The effect of immobilization of heparin and bone morphogenic protein-2 to bovine bone substitute on osteoblast-like cell's function.

Authors:  Jung-Bo Huh; Sung-Eun Kim; Se-Kyung Song; Mi-Jung Yun; Ji-Suk Shim; Jeong-Yol Lee; Sang-Wan Shin
Journal:  J Adv Prosthodont       Date:  2011-09-25       Impact factor: 1.904

2.  Integration of Rabbit Adipose Derived Mesenchymal Stem Cells to Hydroxyapatite Burr Hole Button Device for Bone Interface Regeneration.

Authors:  Viswanathan Gayathri; Varma Harikrishnan; Parayanthala Valappil Mohanan
Journal:  Int J Biomater       Date:  2016-01-05

3.  Bio-Oss® modified by calcitonin gene-related peptide promotes osteogenesis in vitro.

Authors:  Yuanjing Li; Lan Yang; Zhichao Zheng; Zhengmao Li; Tian Deng; Wen Ren; Caijuan Wu; Lvhua Guo
Journal:  Exp Ther Med       Date:  2017-08-28       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.